Systematic pan-cancer landscape identifies CARM1 as a potential prognostic and immunological biomarker

• Published in: BMC genetics 2022-01, Vol.23 (1), p.7-7, Article 7
• Main Authors: Qiu, Yingqi, Wang, Hao, Liao, Peiyun, Xu, Binyan, Hu, Rong, Yang, Yulu, Li, Yuhua
• Format: Article
• Language: English
• Subjects: Analysis; Arginine; Bioinformatics; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Blood; Breast cancer; Cancer; Carcinogenesis; Cell growth; Chromatin; Datasets; Development and progression; Diagnosis; DNA binding proteins; Gene expression; Gene regulation; Genes; Genetic aspects; Genetic transcription; Genomes; Histones; Histones - metabolism; Humans; Identification and classification; Immune checkpoint; Immunotherapy; Kinases; Liver cancer; Medical prognosis; Melanoma; Metabolism; Metastases; Metastasis; Methylation; Methyltransferases; Microsatellite instability; Mismatch repair; Neoplasms - diagnosis; Ovarian cancer; Prognosis; Protein arginine methyltransferase; Protein expression; Protein-Arginine N-Methyltransferases - genetics; Proteins; Survival analysis; Transcription; Transcription factors; Tumor microenvironment; Tumor Microenvironment - genetics; Tumorigenesis; Tumors
• ISSN: 2730-6844; 2730-6844; 1471-2156
• DOI: 10.1186/s12863-021-01022-w

Belonging to the protein arginine methyltransferase (PRMT) family, the enzyme encoded by coactivator associated arginine methyltransferase 1 (CARM1) catalyzes the methylation of protein arginine residues, especially acts on histones and other chromatin related proteins, which is essential in regulating gene expression. Beyond its well-established involvement in the regulation of transcription, recent studies have revealed a novel role of CARM1 in tumorigenesis and development, but there is still a lack of systematic understanding of CARM1 in human cancers. An integrated analysis of CARM1 in pan-cancer may contribute to further explore its prognostic value and potential immunological function in tumor therapy. Based on systematic analysis of data in multiple databases, we firstly verified that CARM1 is highly expressed in most tumors compared with corresponding normal tissues, and is bound up with poor prognosis in some tumors. Subsequently, relevance between CARM1 expression level and tumor immune microenvironment is analyzed from the perspectives of tumor mutation burden, microsatellite instability, mismatch repair genes, methyltransferases genes, immune checkpoint genes and immune cells infiltration, indicating a potential relationship between CARM1 expression and tumor microenvironment. A gene enrichment analysis followed shortly, which implied that the role of CARM1 in tumor pathogenesis may be related to transcriptional imbalance and viral carcinogenesis. Our first comprehensive bioinformatics analysis provides a broad molecular perspective on the role of CARM1 in various tumors, highlights its value in clinical prognosis and potential association with tumor immune microenvironment, which may furnish an immune based antitumor strategy to provide a reference for more accurate and personalized immunotherapy in the future.